ViiV
Gilead’s New Drug Application for Yeztugo accepted by US FDA
The investigational once-weekly oral treatment could be the first long-acting pill for HIV prevention
GSK announces bepirovirsen’s ‘functional cure’ data to treat chronic hepatitis B
Over 240 million people worldwide live with chronic hepatitis B
GSK signs agreement with Protas to streamline clinical trials
The new three-year agreement builds on an existing two-year relationship
GSK to acquire 35Pharma for $950m including a potential drug for pulmonary hypertension
PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide
GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults
RSV affects approximately 64 million people around the world each year
GSK’s Nucala approved by MHRA for uncontrolled COPD
Symptoms of COPD include breathlessness, persistent cough and frequent chest infections
GSK’s Blenrep approved by FDA for multiple myeloma
Approval supported by positive results from phase 3 trial
Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use
An estimated 1.2 million people in the US are currently living with the virus
GSK and Hengrui enter multi-programme collaboration agreement worth $12bn
The deal includes a PDE3/4 inhibitor in clinical development for COPD
GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma
More than 50,000 cases of the blood cancer are diagnosed in Europe each year
Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval
More than 100 people in the US were diagnosed with HIV every day in 2023
GSK’s Blenrep combination recommended by NICE to treat multiple myeloma
The decision means that eligible patients in England will be the first in the world to access the combination